Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TC12-1
- Development stage
- Unknown
- Lead developer
- Guizhou Medical University
- Modality
- Small Molecules
01
Overview
TC12-1: sourced facts only. name: "we screened out an effective target, a fluorinated tanshinone analogue (TC12-1), which can effectively inhibit and bind to RECQL4." [PMID:41203034]; target: "we screened out an effective target, a fluorinated tanshinone analogue (TC12-1), which can effectively inhibit and bind to RECQL4." [PMID:41203034]; developer: "Department of Obstetrics and Gynecology, Affiliated Hospital of Guizhou Medical University, Guiyang 550002, China; State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang 550014, China." [PMID:41203034]; modality: "a fluorinated tanshinone analogue (TC12-1)" [PMID:41203034]
02
Targets
RECQL4
Beyond the preview
Go deeper on TC12-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TC12-1.